Oplinc Has Been Serving Oncology Professionals since 1999

Education and support for clinical and administrative staff

Risë Marie Cleland founded Oplinc in 1999 to provide oncology professionals a national perspective on health care and legislative issues and to provide direct assistance with business issues that can be disruptive to patient care if not attended to.

Oplinc understands the challenges facing oncology professionals in today’s healthcare climate and we look to provide some of the tools and resources necessary for successful practice management. Our practical experience in oncology and our national scope allow us to deliver timely and precise materials.

Oplinc’s philosophy is to provide the education and support to both the clinical and administrative staff with an emphasis on building an integrated and cohesive team.

We hope that you will continue to find this site valuable and we welcome your comments and suggestions.

Founder and President
Risë Marie Cleland holds degrees in Human Ecology and Business Management, with a concentration in the effectual aspects of business on society. Ms. Cleland was the Business Director of a cancer research and treatment center before founding Oplinc.

As President of Oplinc, Ms. Cleland has daily contact with oncology practices, payers and pharmaceutical manufacturers. Risë serves as the Executive Director of the Washington State Medical Oncology Society, and is an active member in the American Society of Clinical Oncology (ASCO), serving on ASCO’s Clinical Practice Committee (CPC), CPC Administrator Workgroup and the Practice Policy and Emerging Issues (PPEI) Workgroup. Risë also serves on the Editorial Advisory Board for Oncology Practice Manager (OPM) magazine.

As a national speaker Ms. Cleland has presented educational seminars focusing on best practice standards designed to ensure continued patient access to quality cancer care for the American Society of Clinical Oncology (ASCO), ONS Congress (Oncology Nursing Society), AOHA Conference (Administrators in Oncology Hematology Assembly, and throughout the country at oncology state society and pharmaceutical industry meetings.